We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

Company profile
Ticker
GTHP
Exchange
Website
CEO
Mark Faupel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Masimo • Natus Medical • LivaNova • Outset Medical • Fonar • Cutera • Inmode ...
Former names
SPECTRX INC
SEC CIK
Corporate docs
IRS number
582029543
GTHP stock data
Investment data
Securities sold
Number of investors
Calendar
16 May 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 725K | 725K | 725K | 725K | 725K | 725K |
Cash burn (monthly) | (no burn) | 43.5K | 147.67K | 160.5K | 59.67K | 120.92K |
Cash used (since last report) | n/a | 191.6K | 650.4K | 706.92K | 262.8K | 532.58K |
Cash remaining | n/a | 533.4K | 74.6K | 18.08K | 462.2K | 192.42K |
Runway (months of cash) | n/a | 12.3 | 0.5 | 0.1 | 7.7 | 1.6 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
bore, conflict, deadline, earlier, FINRA, imposed, installment, lock, NMPA, Notification, ongoing, prefunded, Russia, shortly, shown, threshold, tracking, Ukraine, underwritten, unregistered
Removed:
aggregated, amending, appealing, ASU, bearing, bifurcate, bifurcation, called, clarifying, Clavijo, commitment, component, COO, depreciated, disposed, earliest, earn, elimination, EPS, exchangeable, expensing, explained, FASB, Finally, forbearance, GPB, Hedging, henceforth, listed, managing, member, modified, nondetachable, noted, notified, occurrence, offsetting, placement, planning, processing, qualify, ratio, reimburse, remain, removing, restructure, retrospective, Rosenstock, rule, scope, separate, separation, Similarly, simple, simplify, standard, subsequently, Topic, treatment, twelve
Current reports
8-K
Material Modifications to Rights of Security Holders
29 Jul 22
8-K
Material Modifications to Rights of Security Holders
6 Jan 22
8-K
Entry into a Material Definitive Agreement
3 Sep 21
8-K
Submission of Matters to a Vote of Security Holders
27 Jul 21
8-K
Other Events
7 Jul 21
8-K
Entry into a Material Definitive Agreement
10 Jun 21
8-K
Departure of Directors or Certain Officers
16 Sep 20
8-K
Other Events
18 May 20
8-K
Other Events
31 Mar 20
8-K
Departure of Directors or Certain Officers
3 Apr 19
Registration and prospectus
Other
EFFECT
Notice of effectiveness
16 Oct 20
CORRESP
Correspondence with SEC
12 Oct 20
UPLOAD
Letter from SEC
13 Sep 20
EFFECT
Notice of effectiveness
11 Jul 18
CORRESP
Correspondence with SEC
8 Jul 18
UPLOAD
Letter from SEC
1 Jul 18
UPLOAD
Letter from SEC
18 Aug 16
CORRESP
Correspondence with SEC
17 Aug 16
CORRESP
Correspondence with SEC
11 Aug 16
CORRESP
Correspondence with SEC
2 Aug 16
Ownership
SC 13G
GUIDED THERAPEUTICS / Rosalind Advisors ownership change
6 Jul 22
SC 13D
Guided Therapeutics Inc
25 May 18
3
GUIDED THERAPEUTICS / Lynne H Imhoff ownership change
25 May 18
SC 13G
Guided Therapeutics Inc
8 Mar 17
3
GUIDED THERAPEUTICS / Richard P. Blumberg ownership change
17 Nov 16
SC 13G
Guided Therapeutics Inc
17 Apr 16
SC 13G/A
Guided Therapeutics Inc
6 Oct 15
SC 13G
Guided Therapeutics Inc
4 Oct 15
4
GUIDED THERAPEUTICS / John E Imhoff ownership change
16 Jul 15
4
GUIDED THERAPEUTICS / Gene S Cartwright ownership change
16 Jul 15